RT Journal Article
SR Electronic
T1 Emergence and spread of two SARS-CoV-2 variants of interest in Nigeria
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.09.24.22280269
DO 10.1101/2022.09.24.22280269
A1 Olawoye, Idowu B.
A1 Oluniyi, Paul E.
A1 Oguzie, Judith U.
A1 Uwanibe, Jessica N.
A1 Kayode, Adeyemi T.
A1 Olumade, Testimony J.
A1 Ajogbasile, Fehintola V.
A1 Parker, Edyth
A1 Eromon, Philomena E.
A1 Abechi, Priscilla
A1 Sobajo, Tope
A1 Ugwu, Chinedu
A1 Uwem, George
A1 Ayoade, Femi
A1 Akano, Kazeem
A1 Oyejide, Nicholas
A1 Fred-Akintunwa, Iyanuoluwa
A1 Adedotun-Sulaiman, Kemi
A1 Brimmo, Farida
A1 Adegboyega, Benjamin
A1 Philip, Courage
A1 Adeleke, Ayomide
A1 Chukwu, Grace C.
A1 Muhammad, Ahmed I.
A1 Ope-ewe, Oludayo O.
A1 Otitoola, Shobi
A1 Ogunsanya, Olusola A.
A1 Saibu, Mudasiru F.
A1 Sijuwola, Ayotunde E.
A1 Ezekiel, Grace O.
A1 John, Oluwagboadurami G.
A1 Akin-John, Julie O.
A1 Akinlo, Oluwasemilogo O.
A1 Fayemi, Olanrewaju O.
A1 Ipaye, Testimony O.
A1 Nwodo, Deborah C.
A1 Omoniyi, Abolade E.
A1 Omwanghe, Iyobosa B.
A1 Terkuma, Christabel A.
A1 Okolie, Johnson
A1 Ayo-Ale, Olubukola
A1 Ikponmwosa, Odia
A1 Benevolence, Ebo
A1 Naregose, Okonofua
A1 Patience, Akhilomen
A1 Blessing, Osiemi
A1 Micheal, Airende
A1 Jacqueline, Agbukor
A1 John, Aiyepada
A1 Ebhodaghe, Paulson
A1 Racheal, Omiunu
A1 Rita, Esumeh
A1 Rosemary, Giwa
A1 Solomon, Ehikhametalor
A1 Anieno, Ekanem
A1 Edna, Yerumoh
A1 Chris, Aire
A1 Donatus, Adomeh
A1 Ogbaini, Ephraim
A1 Tatfeng, Mirabeau Y.
A1 Omunakwe, Hannah E.
A1 Bob-Manuel, Mienye
A1 Ahmed, Rahaman
A1 Onwuamah, Chika
A1 Shaibu, Joseph
A1 Okwuraiwe, Azuka
A1 Atage, Anthony E.
A1 Bock-Oruma, Andrew
A1 Daramola, Funmi
A1 Fajola, Akinwumi
A1 Ntia, Nsikak-Abasi
A1 Ekpo, Julie J.
A1 Moses, Anietie
A1 Moore-Igwe, Worbianueri B.
A1 Yusuf, Ibrahim F.
A1 Fakayode, Enoch O.
A1 Akinola, Monilade
A1 Kida, Ibrahim
A1 Oderinde, Bamidele S.
A1 Wudiri, Zara
A1 Adeyemi, Olufemi O.
A1 Akanbi, Olusola
A1 Ahumibe, Anthony
A1 Akinpelu, Afolabi
A1 Ayansola, Oyeronke
A1 Babatunde, Olajumoke
A1 Omoare, Adesuyi
A1 Chukwu, Chimaobi
A1 Mba, Nwando
A1 Omoruyi, Ewean C.
A1 Adeniji, Johnson A.
A1 Adewunmi, Moses O.
A1 Olayinka, Oluseyi
A1 Olasunkanmi, Olisa
A1 Akande, Olatunji
A1 Nwafor, Ifeanyi
A1 Ekeh, Matthew
A1 Ndoma, Erim
A1 Ewah, Richard
A1 Duruihuoma, Rosemary
A1 Abu, Augustine
A1 Odeh, Elizabeth
A1 Onyia, Venatious
A1 Ojide, Kingsley C.
A1 Okoro, Sylvanus
A1 Igwe, Daniel
A1 Khan, Kamran
A1 Ajayi, Anthony N.
A1 Ugwu, Ebhodaghe Ngozi
A1 Ugwu, Collins N.
A1 Ukwuaja, Kingsley
A1 Ogah, Emeka O.
A1 Abejegah, Chukwuyem
A1 Adedosu, Nelson
A1 Ayodeji, Olufemi
A1 Isamotu, Rafiu O.
A1 Gadzama, Galadima
A1 Petros, Brittany
A1 Siddle, Katherine J.
A1 Schaffner, Stephen
A1 Akpede, George
A1 Erameh, Cyril Oshomah
A1 Baba, Marycelin
A1 Oladiji, Femi
A1 Audu, Rosemary
A1 Ndodo, Nnaemeka
A1 Fowotade, Adeola
A1 Okogbenin, Sylvanus
A1 Okokhere, Peter
A1 Park, Danny
A1 Mcannis, Bronwyn
A1 Adetifa, Ifedayo
A1 Ihekweazu, Chikwe
A1 Salako, Babatunde L.
A1 Tomori, Oyewale
A1 Happi, Anise N.
A1 Folarin, Onikepe A.
A1 Andersen, Kristian G.
A1 Sabeti, Pardis C.
A1 Happi, Christian T.
YR 2022
UL http://medrxiv.org/content/early/2022/09/25/2022.09.24.22280269.abstract
AB Identifying the dissemination patterns and impacts of a virus of economic or health importance during a pandemic is crucial, as it informs the public on policies for containment in order to reduce the spread of the virus. In this study, we integrated genomic and travel data to investigate the emergence and spread of the B.1.1.318 and B.1.525 variants of interest in Nigeria and the wider Africa region. By integrating travel data and phylogeographic reconstructions, we find that these two variants that arose during the second wave emerged from within Africa, with the B.1.525 from Nigeria, and then spread to other parts of the world. Our results show how regional connectivity in downsampled regions like Africa can often influence virus transmissions between neighbouring countries. Our findings demonstrate the power of genomic analysis when combined with mobility and epidemiological data to identify the drivers of transmission in the region, generating actionable information for public health decision makers in the region.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by TEDs Audacious Project, including the ELMA Foundation MacKenzie Scott the Skoll Foundation and Open Philanthropy. This work was also partly supported by grants from the National Institute of Allergy and Infectious Diseases (https://www.niaid.nih.gov) NIH-H3Africa (https://h3africa.org) (U01HG007480 and U54HG007480) the World Bank (projects ACE-019 and ACE-IMPACT) the Rockefeller Foundation (Grant 2021 HTH) the Africa CDC through the African Society of Laboratory Medicine [ASLM] (Grant INV018978) the Wellcome Trust (Project 216619/Z/19/Z) the WARN-ID/CREID grant U01AI151812 and the Science for Africa FoundationAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The samples used in this study were de-identified from individual labs within Nigeria during routine surveillance and testing of SARS-CoV-2. The National Health Research Ethics Committee of Nigeria (NHREC) gave ethical approval for this work with approval number NHREC/01/01/2007-30/11/2021B.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced are availale online at: https://github.com/acegid/SARS-CoV-2_Manucript_Supplemental_Data https://github.com/acegid/SARS-CoV-2_Manucript_Supplemental_Data